期刊
THERAPEUTIC DELIVERY
卷 8, 期 3, 页码 151-U32出版社
FUTURE SCI LTD
DOI: 10.4155/tde-2016-0068
关键词
lipids; mucosal immunity; nanoparticles; nasal vaccines; polymers
资金
- National Health and Medical Research Council (NHMRC), Australia
- international postgraduate research scholarship (IPRS)
- Australian postgraduate award (APA)
Most pathogens gain access to the human body and initiate systemic infections through mucosal sites. A large number of currently marketed licensed vaccines are parenterally administered; they generate strong systemic immunity but not mucosal immunity. Nasal vaccination is an appealing strategy for the induction of mucosal-specific immunity; however, its development is mostly challenged by several factors, such as inefficient antigen uptake, its rapid mucociliary clearance, size-restricted permeation across epithelial barriers and absence of safe human mucosal adjuvants. Therefore, a safer mucosal-adjuvanting strategy or efficient mucosal delivery platform is much warranted. This review summarizes challenges and the rationale for nasal vaccine development with a special focus on the use of nanoparticles based on polymers and lipids for mucosal vaccine delivery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据